
Sensorium Therapeutics is a pioneering company focused on developing breakthrough psychoactive medicines to address unmet medical needs in mental health and neurological diseases. Utilizing their innovative Biodynamic Discovery Platform™, they integrate advanced chemistry, neuroscience, and machine learning to enhance the drug development process, ensuring the identification of safe and effective neuroactive medicines inspired by natural compounds. Founded by experts from Harvard Medical School and Massachusetts General Hospital, Sensorium is positioned to expand the treatment landscape for conditions such as anxiety and epilepsy, backed by a team with extensive experience in drug discovery and development.

Sensorium Therapeutics is a pioneering company focused on developing breakthrough psychoactive medicines to address unmet medical needs in mental health and neurological diseases. Utilizing their innovative Biodynamic Discovery Platform™, they integrate advanced chemistry, neuroscience, and machine learning to enhance the drug development process, ensuring the identification of safe and effective neuroactive medicines inspired by natural compounds. Founded by experts from Harvard Medical School and Massachusetts General Hospital, Sensorium is positioned to expand the treatment landscape for conditions such as anxiety and epilepsy, backed by a team with extensive experience in drug discovery and development.
Stage: Clinical-stage
Lead program: SNTX-2643 (SENS-01), rapid-acting anxiolytic
Platform: Biodynamic Discovery / SensAI platform (AI + chemistry + neuroscience)
Founded: 2021 (Boston, MA)
Known funding: $55M total (Series A $30M + $25M extension)
Mental health and neurological diseases (CNS therapeutics, anxiety, epilepsy)
2021
Biotechnology
$30,000,000
Financing announced to advance SENS-01 and the Biodynamic Discovery Platform
$25,000,000
Series A extension reported by company news
“Includes participation from Santé Ventures, Route 66 Ventures, CU Healthcare Innovation Fund and a broader syndicate including investors listed by the company”